Group 1 - The stock price of Koyuan Pharmaceutical (301281) closed at 36.95 yuan on August 1, 2025, down 3.58% with a turnover rate of 9.41% and a trading volume of 64,800 hands, amounting to 244 million yuan [1] - The latest financial report for Koyuan Pharmaceutical shows total revenue of 111 million yuan for Q1 2025, a year-on-year decrease of 23.98%, while net profit attributable to shareholders was 23.08 million yuan, an increase of 7.25% [1] - The company has a current ratio of 6.622, a quick ratio of 5.235, and a debt-to-asset ratio of 12.23% [1] Group 2 - Koyuan Pharmaceutical has made investments in 5 companies and participated in 108 bidding projects [2] - The company holds 3 trademark registrations and 65 patents, along with 81 administrative licenses [2]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 708,000 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share raw material pharmaceutical sector is 608,400 yuan [2] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [2] - The top five highest-paid company secretaries have annual salaries of 1.9309 million yuan, 1.514 million yuan, 1.2 million yuan, 1.17 million yuan, and 1.1 million yuan respectively [2] Age and Education Distribution - Company secretaries aged between 30 and 50 constitute 60% of the market, while those over 50 account for 38%, and those aged 30 or below make up 2% [1] - More than half of the company secretaries hold a bachelor's degree, with 9% having an associate degree, 52% a bachelor's degree, and 39% a master's degree [1] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [2] - The top five companies with the most investor meetings conducted 520, 437, 325, 323, and 291 meetings respectively [3]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Over 21% of company secretaries earn more than 1 million yuan annually, indicating a significant portion of high earners in this role [1] Salary Distribution - The average annual salary for secretaries in the A-share pharmaceutical sector is 608,400 yuan [5] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [5] - The top five highest-paid secretaries have salaries ranging from 1.0832 million to 1.9309 million yuan, with varying years of service [7] Age and Education Demographics - The majority of company secretaries (60%) are aged between 30 and 50 years, while 38% are over 50 years, and only 2% are 30 years or younger [1] - More than half (52%) of the secretaries hold a bachelor's degree, with 39% holding a master's degree and 9% holding an associate degree [3] Investor Relations - There is a significant variance in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [9] - The five companies with the highest number of investor meetings range from 291 to 520 meetings per year, with their secretaries' salaries varying widely [9]

Core Insights - The report highlights that in 2024, the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share raw material pharmaceutical sector is 608,400 yuan [5] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [5] Age and Education Distribution - Company secretaries aged between 30 and 50 constitute 60% of the market, while those over 50 account for 38%, and those aged 30 or below make up 2% [3] - Over half of the company secretaries hold a bachelor's degree, with the breakdown being 9% with an associate degree, 52% with a bachelor's degree, and 39% with a master's degree [3] Top and Bottom Salaries - The top five highest-paid company secretaries have annual salaries of 1.9309 million yuan, 1.514 million yuan, 1.2 million yuan, 1.176 million yuan, and 1.0832 million yuan, respectively [7] - The three lowest-paid company secretaries earn 174,200 yuan, 187,500 yuan, and 190,700 yuan, all of whom have served in their positions for less than two years [7] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [9] - Five companies reported zero investor meetings, while the top five companies for investor engagement had between 291 and 520 meetings, with corresponding secretary salaries ranging from 267,000 yuan to 444,200 yuan [9]

证券日报网讯 7月29日晚间，科源制药发布公告称，公司于2025年7月28日召开职工代表大会进行第四 届监事会职工代表监事的补选，经与会职工代表投票，选举林岩先生担任公司第四届监事会职工代表监 事。 （编辑 姚尧） ...

二、补选公司职工代表监事的情况 鉴于李照文先生的辞职将导致公司监事会成员人数低于法定最低人数，且监 事会职工代表监事人数少于监事会成员的三分之一，为保证公司监事会的正常运 行，根据《公司法》《深圳证券交易所上市公司自律监管指引第2号——创业板 上市公司规范运作》及《公司章程》等有关规定，公司于2025年7月28日召开职 工代表大会进行第四届监事会职工代表监事的补选，经与会职工代表投票，选举 林岩先生（简历详见附件）担任公司第四届监事会职工代表监事，任期自本次职 证券代码：301281 证券简称：科源制药 公告编号：2025-050 山东科源制药股份有限公司 关于职工代表监事辞职暨补选的公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、公司职工代表监事辞职的情况 山东科源制药股份有限公司（以下简称"公司"）监事会于近日收到公司职 工代表监事李照文先生的书面辞职报告。李照文先生因退休离任原因申请辞去公 司第四届监事会职工代表监事职务，辞职后李照文先生不在公司担任其他职务。 李照文先生原定任期至第四届监事会届满日（2027年9月29日）。 截至本公告披露日， ...

Core Insights - The company held a mid-year management meeting on July 19 to summarize achievements and shortcomings, analyze industry trends, and set strategic plans for the second half of the year [1][3] - The chairman and CEO, Gao Chunpo, emphasized the current pharmaceutical industry is undergoing a deep adjustment period with intensified competition and ongoing policy impacts, urging the company to find its market position amid these challenges [3][5] Group 1 - Each department head presented their work, achievements, innovations, challenges, and plans for the second half of 2025, showcasing the diligent efforts of the company [3] - Gao Chunpo highlighted the need for a long-term perspective to navigate through cyclical fluctuations and to create new opportunities amid changes [3][5] Group 2 - For the second half of the year, the chairman called for collaborative efforts across systems, focusing on market penetration, operational efficiency, and enhancing product competitiveness through technological improvements [5] - The meeting served as both a review of past work and a motivational rallying point for management to align on goals and drive high-quality development in the face of industry transformation [5]

证券代码：301281 证券简称：科源制药 公告编号：2025-049 山东科源制药股份有限公司 关于持股 5%以上股东股份减持触及 1%整数倍的公告 公司持股 5%以上股东问泽鸿先生保证向本公司提供的信息内容真实、准确 和完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 山东科源制药股份有限公司（以下简称"公司"）于近日收到持股5%以上股 东问泽鸿先生出具的《减持进度告知函》，问泽鸿先生于2025年6月27日至2025 年7月4日以集中竞价方式累计减持公司96.69万股，占公司总股本的0.89%。本次 权益变动后，问泽鸿先生持有公司股份743.31万股，占公司总股本的6.86%，权 益变动触及1%的整数倍,现将具体情况公告如下： | 1.基本情况 | | | | --- | --- | --- | | 信息披露义务人 | 问泽鸿 | | | 住所 | | 上海市浦东新区花木路 1883 弄 196 号 | | 权益变动时间 | | 2025 年 6 月 27 日至 2025 年 7 月 4 日 | | 权益变动过程 ...

Group 1 - Taotao Automotive expects a net profit of 310 million to 360 million yuan for the first half of 2025, representing a year-on-year increase of 70.34% to 97.81% [1] - The company specializes in the research, production, and sales of all-terrain vehicles, electric golf carts, electric scooters, electric balance bikes, electric bicycles, and their accessories [1] - China Communications Construction Company plans to repurchase shares worth between 500 million to 1 billion yuan, with a maximum repurchase price of 13.58 yuan per share [1][2] Group 2 - Annoqi's subsidiary received a government subsidy of 1.65 million yuan, accounting for 34.77% of the company's latest audited net profit [2] - Annoqi focuses on the research, production, and sales of mid-to-high-end differentiated dyes [3] - Minfeng Special Paper announced the complete shutdown of its Nanhu plant, as its Haiyan plant is now capable of handling the production capacity [4] Group 3 - Aoto Electronics received a trademark registration certificate from Saudi Arabia, covering various electronic products [5] - Landi Group plans to acquire up to 20.1667% of the shares of Jujia Technology for a total price not exceeding 121 million yuan [6][7] - Lifan Pharmaceutical's Danpi phenol raw material drug has been approved for market launch, utilizing a new process that enhances efficiency and meets market demand [8] Group 4 - Shanghai Construction received a total of 548 million yuan in government subsidies, which accounts for 22.79% of the company's latest audited net profit [8] - Wanbangde's subsidiary received ethical approval for a key clinical trial of a new drug for Alzheimer's disease [8] - Prolo Pharmaceutical's subsidiary received approval for the market launch of a new raw material drug for liver cancer treatment [9] Group 5 - Chenguang New Materials received a government subsidy of 26 million yuan, representing 62.86% of the company's latest audited net profit [10] - Sanyou Medical's subsidiary received a government subsidy of 331,000 yuan, accounting for 28.86% of the company's latest audited net profit [11] - Weichai Heavy Machinery expects a net profit of 132 million to 151 million yuan for the first half of 2025, reflecting a year-on-year increase of 40% to 60% [12] Group 6 - Guanhao Biological announced the termination of its application for a specific stock issuance [13] - China Film plans to use up to 1.5 billion yuan of idle funds for cash management [14] - Aotai Biological intends to use up to 480 million yuan of idle raised funds for cash management [15] Group 7 - Helin Micro-Nano is planning to issue overseas shares and list on the Hong Kong Stock Exchange [17] - Jinpan Technology's vice president resigned due to personal health reasons [18] - Tongyi Zhong's chairman and general manager plan to reduce their shareholdings in the company [19] Group 8 - Naipu Mining signed an overseas contract worth 18.85 million USD [21] - Zhengye Technology completed an asset sale transaction worth 178 million yuan [23] - Lianxin Equipment won a bid for a project worth 157 million yuan from BOE [24] Group 9 - Smart Control plans to apply for a comprehensive credit line of up to 260 million yuan from banks [25] - Keyuan Pharmaceutical's application for issuing shares to purchase assets has been accepted by the Shenzhen Stock Exchange [27] - Meige Intelligent's H-share listing application materials have been received by the China Securities Regulatory Commission [29] Group 10 - Siwei Tuxin's subsidiary submitted an H-share listing application [32] - Metro Design's application for issuing shares to purchase assets has been accepted by the Shenzhen Stock Exchange [32] - Aeston submitted an application for H-share listing [34] Group 11 - Jiu Ri New Materials' shareholders plan to reduce their holdings by a total of 98,900 shares [34] - Yihua Tong's shareholder plans to reduce their holdings by up to 700,000 shares [35] - Xishanghai plans to distribute a cash dividend of 0.08 yuan per share [36] Group 12 - Zhejiang Natural plans to distribute a cash dividend of 1.97 yuan for every 10 shares [37] - Kouzi Jiao plans to distribute a cash dividend of 1.30 yuan per share [38] - Huitong Group plans to distribute a cash dividend of 0.023 yuan per share [40] Group 13 - Tongyong Co. plans to reduce its holdings by up to 0.31% of the company's shares [41] - China Shenhua plans to distribute a cash dividend of 2.26 yuan for every 10 shares [43] - Huangting International's executive director resigned due to personal reasons [45] Group 14 - Jinkai New Energy plans to distribute a cash dividend of 1 yuan for every 10 shares [46] - Heimu Dan plans to distribute a cash dividend of 0.041 yuan per share [47] - Feiyada plans to acquire all or part of the controlling stake in Chang Kong Gear [48]

Group 1 - Siwei Tuxin (002405) has submitted an application for the initial public offering of overseas listed shares (H shares) to the Hong Kong Stock Exchange on June 27, 2025, and published the application materials on the same day [1] - The company holds 45.32% of the voting rights in Siwei Zhilian [1] - Megmeet Smart (002881) has had its application materials for the issuance of overseas listed shares (H shares) accepted by the China Securities Regulatory Commission [1] - Keyuan Pharmaceutical (301281) has had its application documents for issuing shares to purchase assets and raising supporting funds accepted by the Shenzhen Stock Exchange [1]